Liminatus Research Development from 2010 to 2026
| LIMN Stock | 0.24 0.02 7.69% |
Research Development | First Reported 2010-12-31 | Previous Quarter 2.4 M | Current Value 2.4 M | Quarterly Volatility 654.1 K |
Check Liminatus Pharma financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Liminatus Pharma's main balance sheet or income statement drivers, such as Selling General Administrative of 759 K, Other Operating Expenses of 3 M or Research Development of 2.4 M, as well as many indicators such as Price To Sales Ratio of 0.0, Dividend Yield of 0.0 or Days Sales Outstanding of 0.0. Liminatus financial statements analysis is a perfect complement when working with Liminatus Pharma Valuation or Volatility modules.
Liminatus | Research Development | Build AI portfolio with Liminatus Stock |
Evaluating Liminatus Pharma's Research Development across multiple reporting periods reveals the company's ability to sustain growth and manage resources effectively. This longitudinal analysis highlights inflection points, cyclical patterns, and structural changes that short-term snapshots might miss, offering deeper insight into Liminatus Pharma Class's fundamental strength.
Latest Liminatus Pharma's Research Development Growth Pattern
Below is the plot of the Research Development of Liminatus Pharma Class over the last few years. It is Liminatus Pharma's Research Development historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Liminatus Pharma's overall financial position and show how it may be relating to other accounts over time.
| Research Development | 10 Years Trend |
|
Research Development |
| Timeline |
Liminatus Research Development Regression Statistics
| Arithmetic Mean | 3,456,171 | |
| Geometric Mean | 3,383,260 | |
| Coefficient Of Variation | 18.93 | |
| Mean Deviation | 523,621 | |
| Median | 3,802,000 | |
| Standard Deviation | 654,138 | |
| Sample Variance | 427.9B | |
| Range | 1.9M | |
| R-Value | (0.67) | |
| Mean Square Error | 250.7B | |
| R-Squared | 0.45 | |
| Significance | 0 | |
| Slope | (86,966) | |
| Total Sum of Squares | 6.8T |
Liminatus Research Development History
About Liminatus Pharma Financial Statements
Liminatus Pharma investors utilize fundamental indicators, such as Research Development, to predict how Liminatus Stock might perform in the future. Analyzing these trends over time helps investors make informed market timing decisions. For further insights, please visit our fundamental analysis page.
| Last Reported | Projected for Next Year | ||
| Research Development | 2.4 M | 2.4 M |
Pair Trading with Liminatus Pharma
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Liminatus Pharma position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Liminatus Pharma will appreciate offsetting losses from the drop in the long position's value.Moving against Liminatus Stock
| 0.39 | DRUG | Bright Minds Biosciences | PairCorr |
| 0.34 | VERA | Vera Therapeutics | PairCorr |
| 0.32 | DMAC | DiaMedica Therapeutics | PairCorr |
The ability to find closely correlated positions to Liminatus Pharma could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Liminatus Pharma when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Liminatus Pharma - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Liminatus Pharma Class to buy it.
The correlation of Liminatus Pharma is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Liminatus Pharma moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Liminatus Pharma Class moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Liminatus Pharma can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out the analysis of Liminatus Pharma Correlation against competitors. You can also try the Technical Analysis module to check basic technical indicators and analysis based on most latest market data.
Will Biotechnology sector continue expanding? Could Liminatus diversify its offerings? Factors like these will boost the valuation of Liminatus Pharma. Expected growth trajectory for Liminatus significantly influences the price investors are willing to assign. Accurate valuation requires analyzing both current fundamentals and future growth trajectories. Every Liminatus Pharma data point contributes insight, yet successful analysis hinges on identifying the most consequential variables.
Earnings Share (0.16) |
Liminatus Pharma Class's market price often diverges from its book value, the accounting figure shown on Liminatus's balance sheet. Smart investors calculate Liminatus Pharma's intrinsic value - its true economic worth - which may differ significantly from both market price and book value. Seasoned market participants apply comprehensive analytical frameworks to derive fundamental worth and identify mispriced opportunities. Since Liminatus Pharma's trading price responds to investor sentiment, macroeconomic conditions, and market psychology, it can swing far from fundamental value.
Understanding that Liminatus Pharma's value differs from its trading price is crucial, as each reflects different aspects of the company. Evaluating whether Liminatus Pharma represents a sound investment requires analyzing earnings trends, revenue growth, technical signals, industry dynamics, and expert forecasts. However, Liminatus Pharma's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.